Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized Phase II Study of Onartuzumab (MetMAb) in Combination Therapy for Advanced Non-Small Cell Lung Cancer
2011-003719-42Phase 2Completed
- Sponsor
- Genentech
- Start
- Mar 2012
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in non-small cell lung cancer (NSCLC) comparing Onartuzumab + bevacizumab arm with Placebo + bevacizumab arm (2 arms). Primary endpoint: Progression-free survival. Started Mar 2012; status: completed.
02
Drugs
onartuzumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2011-003719-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-003719-42.